title: The analysis of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) immunoreactivity within the microenvironment of the ovarian cancer lesion relative to the applied therapeutic strategy.
abstract: RCAS1 is involved in generating the suppressive profile of the tumor microenvironment that helps cancer cells evade immune surveillance. The status of the cells surrounding the cancer nest may affect both the progression of the cancer and the development of metastases. In cases of ovarian cancer, a large number of patients do not respond to the applied therapy. The patient's response to the applied therapy is directly linked to the status of the tumor microenvironment and the intensity of its suppressive profile. We analyzed the immunoreactivity of RCAS1 on the cells present in the ovarian cancer microenvironment in patients with the disease; these cells included macrophages and carcinoma-associated fibroblasts. Later we analyzed the immunoreactivity levels within these cells, taking into consideration the clinical stage of the cancer and the therapeutic strategy applied, such as the number of chemotherapy regiments, primary cytoreductive surgery, or the presence of advanced ascites. In the patients who did not respond to the therapy we observed significantly higher immunoreactivity levels of RCAS1 within the cancer nest than in those patients who did respond; moreover, in the non-responsive patients we found RCAS1 within both macrophages and carcinoma-associated fibroblasts. RCAS1 staining may provide information about the intensity of the immuno-suppressive microenvironment profile found in cases of ovarian cancer and its intensity may directly relate to the clinical outcome of the disease.
authors.affiliation: Department of Tumor Pathology and Pathomorphology of the Franciszek Lukaszczyk Oncology Center, the Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Jozwicki
authors.forename: Wieslawa
authors.initials: W
authors.lastname: Windorbska
authors.forename: Anna A
authors.initials: AA
authors.lastname: Brozyna
authors.forename: Cezary
authors.initials: C
authors.lastname: Jochymski
authors.forename: Pawel
authors.initials: P
authors.lastname: Basta
authors.forename: Jerzy
authors.initials: J
authors.lastname: Sikora
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Stasienko
authors.forename: Magdalena
authors.initials: M
authors.lastname: Dutsch-Wicherek
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Koper
authors.forename: Lukasz
authors.initials: L
authors.lastname: Wicherek
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism*; D005260:Female; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D008207:Lymphatic Metastasis / Q000473:pathology; D008264:Macrophages / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D059016:Tumor Microenvironment
chemical_list: D000951:Antigens, Neoplasm; C120762:EBAG9 protein, human; D019394:Ki-67 Antigen